Incyte announces skin disease drug venture with Chinese company

13
Advertisement

Incyte and China Medical System Holdings Limited reached an agreement whereby Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of CMS (CMS Skinhealth), for the development and commercialization of povorcitinib.

The agreement calls for research, development, registration, and commercialization of the product in Mainland China, Hong Kong, Macao, Taiwan Region, and eleven Southeast Asian countries, and receive a non-exclusive license to manufacture the product in CMS’ Territory.

Under the agreement, CMS will pay Incyte an upfront payment. Incyte is eligible to receive additional potential development, commercial milestones, and royalties on the licensed product’s net sales in CMS’ territory.

CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo and asthma for patients in mainland China and other nations in Asia. Patients suffering from non-segmental vitiligo lose skin pigment in white patches.

“We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, CEO of Incyte. “There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.”

Advertisement

Huang Anjun, the general manager of CMS Skinhealth, stated that, “We expect that this collaboration will enhance CMS Skinhealth’s portfolio of potential treatments for vitiligo that, if approved, will provide differentiated treatment options for vitiligo patients in China.”

Earlier, Incyte reported promising results from a drug trial for patients suffering from a painful skin condition.

Incyte is based near Wilmington and has nearly 1,500 employees in the area.

Advertisement
Advertisement